Despite Breakthroughs, No Hurry To Venture Into The Microbiome
This article was originally published in Start Up
A few start-ups and their backers have begun to pursue therapeutics for diseases modulated by our commensal, or beneficial, microbial populations. But the science is too new, and the VC world too shaken, to spur a rush to invest.
You may also be interested in...
Only a few biopharmaceutical start-ups have formed in the emerging microbiome space, but VC firm Flagship says its homegrown Seres Health, still somewhat stealthy, is developing a new category of drugs that aim to rebalance microbiome populations causing disease.
NuMe Health Inc. aims to market mixtures of edible substances that will act as "prebiotics" to shift ratios of certain bacteria in the lower intestine. The start-up intends to educate consumers about how "managing the microbiome" with products that are not drugs can positively affect metabolic health. First up: a mixture NuMe expects will improve biomarkers associated with pre-diabetes.
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.